RU2555526C2 - Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий - Google Patents

Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий Download PDF

Info

Publication number
RU2555526C2
RU2555526C2 RU2012140954/10A RU2012140954A RU2555526C2 RU 2555526 C2 RU2555526 C2 RU 2555526C2 RU 2012140954/10 A RU2012140954/10 A RU 2012140954/10A RU 2012140954 A RU2012140954 A RU 2012140954A RU 2555526 C2 RU2555526 C2 RU 2555526C2
Authority
RU
Russia
Prior art keywords
antibody
synuclein
fragment
seq
disease
Prior art date
Application number
RU2012140954/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2012140954A (ru
Inventor
Эва НОРДСТРЕМ
Алекс КАСРАИАН
Моника ЭКБЕРГ
Валентина СКРЕПАНТИ СУНДКВИСТ
Ларс ЛАННФЕЛЬТ
Матс ХОЛЬМКВИСТ
Original Assignee
Байоарктик Ньюросайенс Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоарктик Ньюросайенс Аб filed Critical Байоарктик Ньюросайенс Аб
Publication of RU2012140954A publication Critical patent/RU2012140954A/ru
Application granted granted Critical
Publication of RU2555526C2 publication Critical patent/RU2555526C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
RU2012140954/10A 2010-02-26 2011-02-25 Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий RU2555526C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30863810P 2010-02-26 2010-02-26
US61/308,638 2010-02-26
US40626010P 2010-10-25 2010-10-25
US61/406,260 2010-10-25
PCT/IB2011/050826 WO2011104696A1 (en) 2010-02-26 2011-02-25 Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies

Publications (2)

Publication Number Publication Date
RU2012140954A RU2012140954A (ru) 2014-04-10
RU2555526C2 true RU2555526C2 (ru) 2015-07-10

Family

ID=44227520

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012140954/10A RU2555526C2 (ru) 2010-02-26 2011-02-25 Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий

Country Status (20)

Country Link
US (4) US8632776B2 (enExample)
EP (1) EP2539366B1 (enExample)
JP (1) JP5894939B2 (enExample)
CN (3) CN110655573B (enExample)
AU (1) AU2011219414B2 (enExample)
CA (1) CA2789963C (enExample)
CY (1) CY1120014T1 (enExample)
DK (1) DK2539366T3 (enExample)
ES (1) ES2661925T3 (enExample)
HR (1) HRP20180230T8 (enExample)
HU (1) HUE038313T2 (enExample)
LT (1) LT2539366T (enExample)
NO (1) NO2539366T3 (enExample)
PL (1) PL2539366T3 (enExample)
PT (1) PT2539366T (enExample)
RS (1) RS57029B1 (enExample)
RU (1) RU2555526C2 (enExample)
SI (1) SI2539366T1 (enExample)
SM (1) SMT201800044T1 (enExample)
WO (1) WO2011104696A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2760334C2 (ru) * 2016-12-22 2021-11-24 Х. Лундбекк А/С Моноклональные антитела к альфа-синуклеину для предотвращения агрегации тау-белка
RU2787039C2 (ru) * 2017-12-15 2022-12-28 Юсб Биофарма Срл Антитела против альфа-синуклеина

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709048T3 (es) 2008-04-29 2019-04-15 Bioarctic Ab Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
US10989718B2 (en) * 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
BR112014017814A8 (pt) * 2012-01-20 2017-07-11 Genzyme Corp Anticorpos anti-cxcr3
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
LT3071597T (lt) 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
CN106661103B (zh) * 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
US10494425B2 (en) * 2015-02-24 2019-12-03 Rpeptide, Llc Anti-amyloid-beta antibodies
EP3091087A1 (en) 2015-05-08 2016-11-09 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP3325506A1 (en) 2015-07-21 2018-05-30 BioArctic AB Method for treatment of traumatic brain injury targeting aggregated peptides
KR102964291B1 (ko) 2015-11-09 2026-05-13 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
MX2018010485A (es) 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
TW202309093A (zh) * 2016-06-02 2023-03-01 英商梅迪繆思有限公司 針對α-突觸核蛋白之抗體及其用途
CA3028035A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
RU2019114679A (ru) 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
EP3555127B1 (en) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, uses and methods
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
WO2018128454A1 (ko) * 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
AU2018255489B2 (en) * 2017-04-21 2024-06-13 Implicit Bioscience Limited CD 14 antagonist antibodies for treating neurodegenerative diseases
IL270361B2 (en) * 2017-05-01 2025-04-01 Univ Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
KR20200007945A (ko) 2017-05-16 2020-01-22 암프리온, 인코퍼레이티드 미스폴딩된 타우 단백질의 검출
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
EP3661961A4 (en) 2017-08-02 2021-04-14 Stressmarq Biosciences Inc. ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
EP3672635A4 (en) * 2017-08-23 2021-05-12 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHOD OF USING THEREOF
RU2657763C1 (ru) * 2017-09-12 2018-06-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ диагностики болезни паркинсона
BR112020009707A2 (pt) * 2017-11-17 2020-10-13 Abl Bio Inc. anticorpos para a-sinucleína e usos dos mesmos
BR112020011875A2 (pt) 2017-12-14 2020-11-24 Abl Bio Inc. anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
EP3728567B1 (en) 2017-12-19 2023-07-05 Chase Therapeutics Corporation Method for assessing a synucleinopathy
JP7498663B2 (ja) * 2017-12-21 2024-06-12 ハー・ルンドベック・アクチエゼルスカベット アルファ－シヌクレイン病のアッセイ、方法、及び治療
CN109957547A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用
CN109957546A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用
US12583894B2 (en) 2018-04-04 2026-03-24 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of Lewy body disorders
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
WO2020023530A2 (en) 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
BR112021006123A2 (pt) * 2018-10-19 2021-07-20 Janssen Vaccines & Prevention B.V. anticorpos anti-sinucleína
TW202039562A (zh) * 2018-12-12 2020-11-01 大陸商上海藥明生物技術有限公司 抗tim-3抗體及其用途
RU2703430C1 (ru) * 2018-12-13 2019-10-16 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
WO2020192754A1 (en) * 2019-03-28 2020-10-01 The Chinese University Of Hong Kong Sumo peptides for treating neurodegenerative diseases
US20220214360A1 (en) 2019-04-30 2022-07-07 Chase Therapeutics Corporation Alpha-synuclein assays
US20220291240A1 (en) * 2019-08-27 2022-09-15 The Johns Hopkins University Biomarkers for neurodegenerative disorders
PH12022551608A1 (en) 2019-12-31 2023-10-16 Chase Therapeutics Corp Kinases as biomarkers for neurodegenerative conditions
CN111171152B (zh) * 2020-01-15 2023-04-18 吉林医药学院 Pcsk9抗体及其制备方法和应用
NL2025332B1 (en) 2020-04-10 2021-10-26 Syngle Therapeutics B V Novel alpha-synuclein binding antibodies, or antigen binding portions thereof.
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
HRP20250812T1 (hr) * 2020-06-26 2025-09-12 Bioarctic Ab Antitijela koja vežu alfa-sinuklein protofibril
US20230365665A1 (en) 2020-09-17 2023-11-16 Qatar Foundation For Education, Science And Community Development ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
KR20230157296A (ko) * 2020-12-16 2023-11-16 보이저 테라퓨틱스, 인크. 타우 결합 화합물
JP2024525559A (ja) 2021-07-09 2024-07-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病治療用バイオマーカー
CA3230148A1 (en) 2021-08-30 2023-03-09 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
KR20240142535A (ko) 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
JP2023132247A (ja) * 2022-03-10 2023-09-22 公立大学法人大阪 シヌクレイノパシー検出用バイオマーカー及びその利用
CN117430686B (zh) * 2022-07-22 2025-07-01 深圳市安群生物工程有限公司 α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用
CN116589567B (zh) * 2022-11-30 2024-03-19 西南大学 马铃薯x病毒单克隆抗体pvx-2及其应用
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
CN119101159A (zh) * 2024-08-30 2024-12-10 山东大学 抗tim-3单克隆抗体及其制备方法和应用
WO2026068513A1 (en) 2024-09-24 2026-04-02 Bioarctic Ab Bispecific binding molecule

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133521A2 (en) * 2008-04-29 2009-11-05 Bioartic Neuroscience Ab Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002053A2 (en) 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
US20060018918A1 (en) 2000-12-27 2006-01-26 Board Of Regents, The University Of Texas System Production of stabilized conformational isomers of disease associated proteins
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
UA93653C2 (ru) * 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JP2009525046A (ja) 2006-01-31 2009-07-09 エラン ファーマシューティカルズ，インコーポレイテッド アルファ−シヌクレインキナーゼ
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CN101161245B (zh) * 2007-11-29 2011-11-09 首都医科大学宣武医院 二苯乙烯苷及其衍生物抑制突触核蛋白过度表达的用途
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133521A2 (en) * 2008-04-29 2009-11-05 Bioartic Neuroscience Ab Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2760334C2 (ru) * 2016-12-22 2021-11-24 Х. Лундбекк А/С Моноклональные антитела к альфа-синуклеину для предотвращения агрегации тау-белка
RU2787039C2 (ru) * 2017-12-15 2022-12-28 Юсб Биофарма Срл Антитела против альфа-синуклеина
RU2798399C2 (ru) * 2017-12-15 2023-06-22 Юсб Биофарма Срл Антитела
RU2812765C2 (ru) * 2018-12-14 2024-02-02 Эли Лилли Энд Компани Антитела к альфа-синуклеину и варианты их применения

Also Published As

Publication number Publication date
EP2539366A1 (en) 2013-01-02
US8632776B2 (en) 2014-01-21
CN110655573B (zh) 2023-07-18
LT2539366T (lt) 2018-04-25
US20120308572A1 (en) 2012-12-06
CN110655573A (zh) 2020-01-07
AU2011219414B2 (en) 2014-11-20
HRP20180230T1 (hr) 2018-03-09
CY1120014T1 (el) 2018-12-12
HUE038313T2 (hu) 2018-10-29
US9084832B2 (en) 2015-07-21
US20130309251A1 (en) 2013-11-21
CA2789963C (en) 2019-09-03
SI2539366T1 (en) 2018-05-31
JP5894939B2 (ja) 2016-03-30
HRP20180230T8 (hr) 2021-04-30
CN106397588A (zh) 2017-02-15
CN106397588B (zh) 2020-09-08
EP2539366B1 (en) 2017-11-08
CN102869680A (zh) 2013-01-09
DK2539366T3 (en) 2018-02-05
US20150139900A1 (en) 2015-05-21
NO2539366T3 (enExample) 2018-04-07
CA2789963A1 (en) 2011-09-01
PT2539366T (pt) 2018-02-13
US8968734B2 (en) 2015-03-03
US8859501B2 (en) 2014-10-14
RS57029B1 (sr) 2018-05-31
US20140363447A1 (en) 2014-12-11
PL2539366T3 (pl) 2018-06-29
ES2661925T3 (es) 2018-04-04
JP2013525266A (ja) 2013-06-20
SMT201800044T1 (it) 2018-05-02
AU2011219414A1 (en) 2012-09-06
CN102869680B (zh) 2016-10-05
RU2012140954A (ru) 2014-04-10
WO2011104696A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
US8968734B2 (en) Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other α-synucleinopathies
US10208111B2 (en) Alpha-synuclein antibodies and uses thereof
JP2016104727A (ja) タウオリゴマーに結合する抗体
WO2009099176A1 (ja) Aβオリゴマーに特異的に結合する抗体およびその利用
KR20230039734A (ko) 항-Aβ 항체
JP2021509012A (ja) 抗αシヌクレイン抗体
US20230365665A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
KR20250150001A (ko) 항-Aβ 항체를 이용한 신경계 장애의 치료 방법
KR20170087472A (ko) 아밀로이드 β의 22번 위치 및 23번 위치의 턴 구조를 극히 특이적으로 인식하는 항체